M&A Deal Summary

Edwards Acquires ev3 - Percutaneous Heart Valve Technology

On September 29, 2004, Edwards acquired business services company ev3 - Percutaneous Heart Valve Technology from ev3 for 15M USD

Acquisition Highlights
  • This is Edwards’ 1st transaction in the Business Services sector.
  • This is Edwards’ 10th largest (disclosed) transaction.
  • This is Edwards’ 3rd transaction in the United States.
  • This is Edwards’ 1st transaction in Minnesota.

M&A Deal Summary
Date 2004-09-29
Target ev3 - Percutaneous Heart Valve Technology
Sector Business Services
Buyer(s) Edwards
Sellers(s) ev3
Deal Type Divestiture
Deal Value 15M USD

Target

ev3 - Percutaneous Heart Valve Technology

Plymouth, Minnesota, United States
ev3, Inc. - Percutaneous Heart Valve Technology is a provider of percutaneous mitral valve repair program.

Search 193,711 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Edwards

Irvine, California, United States

website

Category Company
Founded 1958
Sector Medical Products
Employees17,300
Revenue 5.4B USD (2022)
DESCRIPTION
Entrance to Edwards Lifesciences' corporate headquarters in Irvine, California.
Entrance to Edwards Lifesciences' corporate headquarters in Irvine, California.

Edwards is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. Edwards was incorporated in 1958 and is based in Irvine, California.

DEAL STATS #
Overall 5 of 13
Sector (Business Services) 1 of 1
Type (Divestiture) 3 of 5
State (Minnesota) 1 of 1
Country (United States) 3 of 9
Year (2004) 1 of 1
Size (of disclosed) 10 of 10
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2003-12-15 Percutaneous Valve Technologies

Fort Lee, New Jersey, United States

Percutaneous Valve Technologies, Inc. is a privately held medical technology company developing an innovative, percutaneous approach for delivering heart valves to treat late-stage aortic stenosis.

Buy $125M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2006-12-04 Edwards Lifesciences - Angiogenesis Program

Irvine, California, United States

Edwards Lifesciences Corp. - Angiogenesis Program provides life science reasearch on proprietary zinc finger protein (ZFP) platform.

Sell -

Seller(S) 1

SELLER

ev3

Plymouth, Minnesota, United States

website

Category Company
Founded 2000
Sector Healthcare Services
Employees1,350
DESCRIPTION

ev3 is the endovascular technology company that brings together the right people, technology, and resources to successfully identify and provide meaningful clinical solutions to underserved markets in the endovascular field. ev3 has been dedicated to developing breakthrough and clinically proven technologies for the endovascular treatment of peripheral vascular and neurovascular diseases.

DEAL STATS #
Overall 1 of 1
Sector (Business Services) 1 of 1
Type (Divestiture) 1 of 1
State (Minnesota) 1 of 1
Country (United States) 1 of 1
Year (2004) 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2006-01-06 Micro Therapeutics

Irvine, California, United States

Micro Therapeutics is a develops, manufactures and markets minimally invasive medical devices for the diagnosis and treatment of vascular disease. The company is focused on catheter-based, or endovascular, technologies for the minimally invasive treatment of neurovascular disorders of the brain associated with stroke.

Buy -
Mergr

Product

Company

Legal